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Polymorphonuclear  leukocytes  have  the  capacity  to  supply  proteolytic 
enzymes capable of generating kinin activity from a plasma protein substrate, 
kininogen,  under  diverse  reaction  conditions  (1-3).  Experiments,  initially 
directed  toward  the  mechanism  of  neutrophil-dependent  kinin  generation, 
have  uncovered  a  different  system  which  is  controlled  by  ec-l-antitrypsin. 
Incubation of crude neutrophil  homogenates with heated human plasma gen- 
erated a biologically  active neutral peptide, distinct from bradykinin,  derived 
from a plasma protein substrate chromatographically separable from kininogen. 
The neutrophil  enzyme responsible  for the formation of neutral peptide was a 
serine-dependent  protease  sensitive  to  inhibition  by  plant-derived  trypsin 
inhibitors and a-l-antitrypsin. 
Materials and Methods 
Bradykinin triacetate  (Sandoz Pharmaceutical, Ltd., Basel, Switzerland); hexadimethrine 
bromide (Polybrene) and diisopropyl fluorophosphate (DFP) ~ (Aldrich Chemical Co., Inc., 
Milwaukee, Wisc.); disodium ethylenediamine tetraacetate  (EDTA) and tris hydroxymethyl 
aminoethane  (Tris)  (Fisher Scientific Co., Fair Lawn, N.  J.); lima bean trypsin  inhibitor 
(LBTI),  soybean  trypsin  inhibitor  (SBTI),  pancreatic  trypsin  inhibitor  (PI),  ovomucoid 
trypsin inhibitor (OMTI), trypsin and chymotrypsin (Worthington Biochemical Corp., Free- 
hold, N. J.); Hanks' balanced salt solution (Microbiological  Associates, Inc., Bethesda, Md.); 
Ficoll, Blue dextran 2000, aldolase, ovalbumin, quaternary aminoethyl (QAE) Sephadex A-25, 
Sephadex G-15, Sephadex G-150, Sepharose 4B (Pharmacia Fine Chemicals, Inc., Piscataway, 
N. J.); human serum albumin (Schwartz/Mann  Div., Becton, Dickinson & Co., Orangeburg, 
N. Y.); vitamin BI2 (Eli Lilly and Co., Indianapolis, Ind.); sodium diatrizoate  (Hypaque) 
(Winthrop Laboratories, N. Y.); and goat antihuman alpha1 trypsin inhibitor (Miles Labora- 
tory, Kankakee, Ill.) were obtained as noted, o~-l-antitrypsin and ot-2-macroglobulin  (4) and 
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slow reacting substance of anaphylaxis (SRS-A) (5) were purified as previously described. The 
(null) a-l-antitrypsin-deficient plasma was obtained by Dr. Charles Reed (Univ. of Wiscon- 
sin)  from the proband (6). 
Column chromatography was carried out at 4°C. Sephadex G-15 and Sepharose 4B filtration 
were performed with a 1.5 cm X  90-cm glass column with a flow rate of 10.0 ml/h and a collec- 
tion vol of 1.71 ml/tube. QAE Sephadex A-25 chromatography employed a 4.8 cm >( 55-cm 
glass column with a flow rate of 50 ml/h and a collection vol of 12 ml/tube. Sephadex G-150 
filtration was carried out in a 2.5 cm X  160-cm glass column pumped against gravity at a flow 
rate of 10 ml/h and a collection vol of 3 ml/tube. Protein was quantitated in column fractions 
by OD at 280 nm utilizing a Beckman DU-2 Spectrophotometer (Beckman Instruments, Inc., 
Fullerton,  Calif.)  or  by  Folin-Ciocalteu reaction.  Chromatographic fractions were concen- 
trated  with positive pressure chambers and  UM-10 membranes  (Amicon Corp., Lexington, 
Mass.).  Unless otherwise indicated centrifugation steps were carried out at 4°C in an Inter- 
national PR-2 or PR-6 centrifuge (International Equipment Co., Needham Heights, Mass.). 
Smooth muscle contractile activity was routinely measured  on an  isolated, atropinized, 
mepyraminized guinea pig ileum  obtained from 200-g  Hartley  guinea pigs;  the ileum was 
suspended  in  Tyrode's  solution  and  the  contractile  response  standardized  with  synthetic 
bradykinin  (7)  and  expressed  as nanogram  bradykinin  equivalent  (ng BK  Eq).  Kininlike 
activity was assessed  on the estrous rat uterus suspended in DeJalon's solution (7). Reaction 
mixtures were directly bioassayed unless the procedure specifies concentration by lyophiliza- 
tion or flask evaporation. 
Preparation of Crude Neutrophil Extract.--Human  neutrophils and mononuclear leukocytes 
were isolated and purified from whole human blood by dextran sedimentation of red blood cells 
and fractionation of white blood cells by centrifugation on Ficoll-Hypaque cushions (8). Puri- 
fied neutrophils were suspended in Hanks' solution  (10 s neutrophils/ml)  and broken by re- 
peated freezing with dry ice in acetone and thawing at room temperature. Broken cells were 
further fragmented for 3 min at 4°C by means of exposure to a probe sonicator (Ultrasonics 
Instruments International,  Inc., Farmingdale, N. Y.). The cell debris was removed by cen- 
trifugation at 400 g for 20 min, and the supernate was retained as crude neutrophil extract. 
Preparation of Heat-Inactivated Plasma.--Whole human  blood,  collected in  EDTA  (1.0 
mg/ml) and hexadimethrine bromide (36.5/zg/ml), was centrifuged at 900 g for 20 rain and the 
supernatant plasma harvested. Plasma was then heated for 2 h at 61°C to inactivate inhibitors, 
proteolytic enzymes, and  plasma kallikrein,  and  centrifuged at 900  g for 5 rain  to remove 
precipitated materials. The resulting supernate was employed as heat-inactivated plasma. A 
variety of normal human donors were utilized interchangeably as sources for crude neutrophil 
extract and heat-inactivated plasma. 
RESULTS 
The  time-course  of generation  of the ileal contracting  principle was  studied 
at  37°C  in  replicate  reaction  mixtures  containing  100  #1  of  crude  neutrophil 
extract  derived  from  10;  neutrophils  and  900  ~1  of  heat-inactivated  plasma. 
The  reaction  was  stopped  at varying time intervals  by  addition  of 4.0 ml ice- 
cold absolute  ethanol.  After centrifugation  for  10  min  at  4°C,  the  supernate, 
which  contained  at  least  90 %  of the  contractile  activity  generated,  was  flask 
evaporated  to  dryness  and  resuspended  in  distilled  water  for  bioassay.  As 
depicted  in  Fig.  1,  the  generation  of  contractile  activity  proceeded  rapidly, 
with the appearance  by  10 rain  of 50%  of the maximal  activity demonstrable 
at  2 h. The pH of the standard  reaction mixture of undiluted,  heat-inactivated 814  GENERATING PATHWAY FOR NEUTRAL PEPTIDE 
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FIG. 1.  Time-course of generation of contractile activity from crude neutrophil extract 
and heat-inactivated plasma. 1,624 ng BK Eq/ml of contractile activity were present at 120 
min and represent 100% of available activity. 
plasma and crude neutrophil extract was 7.8-8.0, representing the upper range 
of a broad pH optimum of pH 5.0-8.2. 
Neutral Peptide.-- 
Physical characteristics:  In order to achieve partial purification and to deter- 
mine the approximate size of the contractile principle, 10,000 ng BK Eq were 
generated from 4.5  ml  of heat-inactivated plasma  by incubation with  500 #1 
of neutrophil extract from 5 X  107 neutrophils for 60 min at 37°C. The activity 
recovered from  the  supernatant  after  80%  ethanol  precipitation  was  flask 
evaporated, resuspended in 1.0 ml of 0.01 M  acetic acid and filtered through a 
previously calibrated Sephadex G-15 column equilibrated in 0.01 M acetic acid. 
Individual fractions were bioassayed, and a single peak of contractile activity 
containing 90 % of that applied was found (Fig. 2) corresponding to the brady- 
kinin marker at 65 % bed vol and consistent with a tool wt of approximately 
1,000. 
In order to define the charge of the contractile principle, 1,000 ng BK Eq of 
Sephadex G-15  purified material were subjected to isoelectric focusing in 4 % 
acrylamide gels  using pH  3.0-10.0  and  subsequently pH  5.0-8.0 ampholytes 
(9). The gels were sliced into 5-mm long cross-sections, washed, eluted in 500 
~l  distilled water for 12 h  at 4°C,  and bioassayed after determining the pH. 
Activity was found only in fractions which corresponded to pH  7.0-8.0 with 
pH  3.0-10.0  ampholytes  and  to  pH  7.3-7.5  with  pH  5.0-8.0  ampholytes; 
recovery was 35-40 % of the activity applied. 
The neutral isoelectric point of the contractile activity clearly distinguished 
it from the cationic peptide, bradykinin. In order to explore further the func- 
tional homogeneity of the Sephadex G-15 purified principle,  100 #1 of 0.01  M 
acetic acid containing 1,000 ng BK Eq of activity were subjected to descending 
paper chromatography in butanol:acetic acid:water (4:1:5) for 12 h at room 
temperature with DNP-lysine as a reference marker (10). The paper strip was 
cut  transversely into  2-cm  pieces and  each  was  eluted  with  3.0  ml  0.01  M BRUCE  U.  WINTROUB,  EDWARD  J.  GOETZL,  K.  FRANK  AUSTEN  815 
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Sephadex G-15 chromatography of contractile activity.  FIG. 2. 
acetic acid.  Eluate fractions were lyophilized, resuspended in  1 ml  Tyrode's 
solution, and bioassayed. Activity was found in a single peak, representing 10 % 
of the starting activity, which migrated 4-8 cm from the origin, and had an 
Rf of 0.25 with respect to DNP-lysine. 
Susceptibility  to inactivation by chymotrypsin and trypsin:  In order to deter- 
mine if the active principle was a peptide, its susceptibility to chymotrypsin 
and trypsin inactivation was compared to that of bradykinin. 200 ng BK Eq 
of Sephadex G-15 purified contractile principle or 400 ng of bradykinin in 100 
~| of Tris:acetate pH 7.8 buffer were incubated with 1.0 mg chymotrypsin or 
1.0 mg trypsin in 900 #1 of the same buffer for 30 rain at 37°C. The reaction 
mixtures  and  control  solutions  of contractile principle  and  bradykinin  were 
boiled for 15 rain. Direct bioassay of the mixtures revealed that both enzymes 
completely inactivated the neutral  contractile principle while bradykinin was 
susceptible only to chymotrypsin. Taken together with the physical chemical 
data,  these studies permit designation of the  active principle as .neutral pep- 
tide. 
Biologic  activity:  The  contraction  of  the  atropinized  and  antihistamine- 
treated guinea pig ileum elicited by crude or partially purified neutral peptide 
was  slow  and more reminiscent of the action of SRS-A  than of histamine or 
bradykinin.  Repeated maximal  contractions were not associated  with  tachy- 
phylaxis. A concentration of neutral peptide equal to 13 ng BK Eq as assayed 
on the guinea pig ileum recorded less than a 0.4 ng BK Eq on the estrous rat 
uterus. Thus, neutral peptide did not have the contractile characteristics of a 
kinin peptide. 
Neutrophil  Protease.-- 
Inhibition:  A  100-#l portion of crude neutrophil extract front 107 cells was 
subjected to heating at 60°C for 15 rain before incubation with 900/~1 of heat- 
inactivated  plasma  for  5  rain  at  37°C.  Unheated,  crude  neutrophil  extract 
generated 500 ng BK Eq of neutral peptide, while the heated extract had no 
activity. 
In order to characterize further the heat-labile neutrophil extract protease, 816  GENERATING  PATHWAY  FOR NEUTRAL  PEPTIDE 
100-/zl portions  of neutrophil  extract  from  107  neutrophils  were  exposed  to 
varying doses of DFP in  10/zl  of 0.0035  M  PO4-buffered 0.15  M  NaC1  (pH 
7.4)  for 60 min at 37°C  followed by extensive dialysis in the same buffer to 
remove residual DFP. 50/zl of each reaction mixture were then mixed with 450 
#1 of heat-inactivated plasma, incubated for 5 rain at 37°C, placed on ice, and 
the samples directly bioassayed for neutral peptide. Complete inhibition of the 
neutral peptide-generating activity occurred with 5 X  10  -4 M  DFP consistent 
with a serine at the active site of the heat labile protease in crude neutrophil 
extract. 
The DFP-sensitive neutrophil protease was further characterized by inter- 
acting 50 pl of crude extract from 5 X  106 neutrophils with 50 #l of equimolar 
quantities of lima bean, soybean, pancreatic, and ovomucoid trypsin inhibitors 
for 15 min at 37°C before addition of 450 pl of heat-inactivated plasma. 5 min 
later, the reaction mixtures were placed on ice and the neutral peptide gener- 
ated  was  directly bioassayed. At  a  concentration of 5  X  10-  7 M,  inhibition 
achieved  with  lima  bean  trypsin  inhibitor  was  85%;  with  soybean  trypsin 
inhibitor, 35 %; with pancreatic trypsin inhibitor,  10%; and with ovomucoid 
trypsin inhibitor, 0 % (Fig. 3). 
The susceptibility  of the  neutrophil  serine protease  to  inhibition  by 5  X 
10  -7 M  lima bean and soybean trypsin inhibitors prompted an analysis of the 
effect of  the  major  human  plasma  trypsin  inhibitor,  a-l-antitrypsin.  50-/zl 
portions of extracts from 5 X  106 neutrophils were preincubated for 15 min at 
37°C with 1.1-110 #g of highly purified a-l-antitrypsin or 80 #g of a-2-macro- 
globulin in  100 pl 0.0035  M  POd-buffered 0.15  M  NaCl  (pH 7.4). These mix- 
tures were then incubated with 450/~1  heat-inactivated plasma  for 5 min at 
37°C and placed on ice before bioassay. Fig. 4 demonstrates a linear relation- 
ship between the percent inhibition of neutral peptide generation and the log 
of the a-l-antitrypsin dose. The dose of a-l-antitrypsin capable of inhibiting 
the neutrophil protease from 5  X  106 cells by 50% was  11 pg, which is less 
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FiG. 3.  LBTI, SBTI, PI, and OMTI inhibition of neutral peptide-generating  activity in 
crude neutrophil extract. The untreated extract generated 330 ng BK Eq/ml neutral peptide. BRUCE  U.  WlNTROUB,  EDWARD J.  GOETZL,  K.  FRANK  AUSTEN  817 
.• 
I00 
80 
6o 
~  20 
o 
I.t  5.5  tt  55  110 
a-I-ANT/TRYPSIN  (lug/Sx IOeNeutrophil$) 
Fxo. 4.  a-l-antitrypsin inhibition  of neutral peptide-generating  activity in crude neutro- 
phil extract. The untreated extract produced  462 ng BK Eq/ml neutral peptide. 
than 1.0% of the normal plasma a-l-antitrypsin level .(11). a-2-macroglobulin 
had no detectable  effect. The  functional integrity of a-2-macroglobulin was 
established by total inhibition of the capacity of kallikrein to generate 500 ng 
of bradykinin from 1.0 ml of heat-inactivated plasma (4). 
The significance of plasma inhibitors other than a-l-antitrypsin was assessed 
by interacting crude neutrophil extract with the plasma of a  patient homo- 
zygous for a-l-antitrypsin deficiency (ZZ)  with 25% of the normal level (11) 
and with the plasma of the patient with no detectable (null) a-l-antitrypsin 
(6). 50/~1 of neutrophil extract were incubated for 30 rain at 37°C with 450/A 
of  whole  unheated  a-l-antitrypsin-deficient  plasma  (null),  a-l-antitrypsin 
deficient plasma  (ZZ)  or whole unheated normal or heat-inactivated plasma. 
The reaction mixtures were placed on ice  and bioassayed. 500  ng BK Eq  of 
activity were generated from (null) a-l-antitrypsin deficient plasma or heat- 
inactivated normal plasma while no activity appeared in a-l-antitrypsin defi- 
cient (ZZ) or unheated normal plasma. Thus, a-l-antitrypsin appeared  to be 
the only significant inhibitor of the neutrophil protease. 
Subcellular  localization:  1.6  X  l0  s  purified  neutrophils  and  1.2  X  l0  s 
mononuclear leukocytes were  homogenized in  20%  sucrose.  25%  by vol  of 
each cell  type was assayed as broken cells  to determine total available sub- 
cellular  enzyme  markers,  neutral  peptide-generating  activity  and  neutral 
peptide-destroying activity. 75%  of each broken  cell  type was  subjected  to 
stepwise, differential centrifugation at 100 g, 400 g, and 17,000 g. Precipitates 
were washed, resuspended in 0.5 ml Hanks' solution, and sonicated for 3 rain 
at 4°C.  100-/A portions of each fraction were assayed for neutral peptide-gen- 
erating or destroying activity and 50-/A portions were assayed for each of the 
subcellular enzyme markers,  lactic dehydrogenase (12),  alkaline phosphatase 
(13),  and/~-glucuronidase (14).  200-#1 portions of each fraction were dialyzed 
for 72  h  at 4°C  against 0.01  M  Tris-buffered 0.15  M  NaC1  (pH  7.4)  before 
assaying for 5'-nucleotidase (15).  Neutral peptide destruction was assessed by 
addition of 100 ng BK Eq of Sephadex G-15 purified neutral peptide to 100 ~1 818  GENERATING PATHWAY  FOR  NEUTRAL  PEPTIDE 
of  each  subcellular  fraction,  incubation  for 30  min  at  37°C,  and  immediate 
bioassay  of  iced  mixtures.  90%  of  the  starting  neutral  peptide-generating 
activity  was  associated  with  55 %  of  the  membrane  marker  5'-nucleotidase 
(16)  in  the  100  g precipitate fraction while less than  5 %  of the  activity was 
present in each of the 400 g or 17,000  g precipitate fractions and none in  the 
17,000  g supernate  (Fig.  5)./~-glucuronidase  and  alkaline phosphatase,  which 
are lysosomal markers  (17),  were most prominent in  the  17,000  g precipitate 
while lactic dehydrogenase, a cytoplasmic marker (17), was principally localized 
in the  17,000 g supernate. The 400 g fraction contained only isolated nuclei by 
phase microscopic examination. Ability to destroy neutral peptide was absent 
in  the  broken cell preparation  but  was  associated with  the  100  g  subcellular 
FIG. 5.  Stepwise, differential centrifugation of purified, disrupted human neutrophils and 
assay  for neutral  peptide-generating activity  and  subcellular fraction  markers. Th  teotal 
activity was 586 mg NADH utilized/h at pH 7.5, 25°C of lactic dehydrogenase, 357 ~zM p-NO2 
phenol generation at pH 10.5, 37°C of alkaline phosphatase, 163 /zg phenolphthalein gen- 
erated/h at pH 6.8, 37°C of/~-glucuronidase, 246/~g phosphate generated/h at pH 7.5, 37°C 
of 5t-nucleotidase, and 5,010 ng BK Eq neutral peptide/1.2  )<  106 neutrophils of neutrophil 
protease. 
fraction.  Mononuclear  cells  manifested  no  neutral  peptide-generating  or  de- 
stroying activity. 
The  finding  that  the  neutral  peptide-generating  activity  was present  only 
with  the  100 g  fraction suggested an association with  the membrane or some 
other rapidly sedimenting debris. Accordingly,  1.0 ml of the crude neutrophil 
extract  routinely used as  a  source of neutral  peptide  generating  activity was 
subjected to gel filtration through Sepharose 4B equilibrated in 0.0035  M  PO4 
buffered 0.15  M  NaCI (pH 7.4).  200 #1 of each column fraction was incubated 
with 200 #1 of heat-inactivated plasma for 10 min at 37°C  before placing the 
samples on ice and direct bioassay of neutral peptide generated. The capacity 
to generate neutral peptide was present only in excluded fractions, in associa- 
tion with 64% of the 5'-nucleotidase activity, and with a  recovery of 90% of 
starting neutral peptide-generating activity. BRUCE  U.  WINTROUB,  EDWARD  ~'.  GOETZL,  K.  FRANK  AUSTEN  819 
Since  the  neutral  peptide-generating activity was  associated with  a  large, 
rapidly sedimenting structure, an attempt was made to inhibit the activity in 
intact and fragmented cells with an inhibitor which might not rapidly penetrate 
the neutrophil. Intact neutrophils were exposed to c~-l-antitrypsin, 260 #g/l@ 
cells in 1.0 ml of Hanks' solution, for 60 rain at 37°C before repeated washing 
and resuspension in 1.0 ml Hanks' solution. 50% of the a-l-antitrypsin treated 
and untreated control cells were then fragmented by freeze-thawing and soni- 
cation.  100 #1 of either intact cells or extract were incubated with 900 ~1 of 
heat-inactivated plasma for 5 rain at 37°C, before addition of 4.0 ml cold etha- 
nol, flask evaporation of the supernate, resuspension in 1.0 ml distilled water 
and bioassay. The neutral  peptide-generating ability of intact cells fell 54% 
from 125  to 58 ng BK Eq/ml  and that  of the subsequently fragmented cells 
46%,  from 838  to 450 ng  BK Eq/ml  after pretreatment of intact cells with 
a-l-antitrypsin. 
Plasma Substrate for  the  Neutrophil  Protease.--lO0  ml  fresh plasma  which 
had been dialyzed for 8 h at 4°C against 5 liters 0.0075  M  Tris:HC1, pH 8.0, 
with two changes of buffer and centrifuged for 20 rain at 4°C  at each buffer 
change to remove precipitated protein, were applied to a QAE Sephadex A-25 
column equilibrated with 0.0075  M Tris: HC1, pH 8.0. The column was washed 
overnight with  starting  buffer and  a  0.3  M  linear sodium  chloride  gradient 
applied. 500-#1 portions of each fraction to be bioassayed for neutral peptide 
activity were heated for 2 h at 61°C before interaction with 50 #1 crude neutro- 
phil extract for 30 rain at 37°C. A single peak of plasma substrate for neutrophil 
protease  was  detected late  in  the  albumin  region  at  12.0  mS  following  the 
kininogen peak at  10.9 mS  (Fig. 6)  with a 61% recovery of starting activity. 
a-l-antitrypsin, as detected by Ouchterlony immunodiffusion, chromatographed 
in the albumin region and overlapped the neutrophil protease plasma substrate 
peak.  Fractions  120-140,  containing  neutrophil  protease  plasma  substrate, 
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FIG. 6.  Plasma  substrate for neutrophil protease and kininogen in the albumin peak of 
plasma chromatographed on QAE Sephadex A-25. Kininogen was assa:yed functionally by 
trypsin cleavage  and release of bradykinin (18). 820  GENERATING PATHWAY FOR NEUTRAL PEPTIDE 
were pooled and  concentrated to  10.0  ml  and  a  3.0-ml  portion was  filtered 
through Sephadex G-150 equilibrated in 0.0035  M  PO4-buffered  0.15 M  NaC1 
(pH  7.4).  Heated fractions were assayed for substrate as above, and a  single 
peak which corresponded to a tool wt of 85-95,000  was detected preceding the 
main protein peak. Kininogen, as assayed functionally by trypsin cleavage and 
release  of bradykinin (18), was not recognized in the filtration step. 
The isolation procedure for substrate was repeated in identical fashion using 
100 ml of plasma from the (null) a-l-antitrypsin-deficient patient. QAE Seph- 
adex A-25  chromatography demonstrated a  single peak  of plasma substrate 
for neutrophil protease which eluted after kininogen at 12.0 mS, and could be 
identified with or without heating.  Heating, however, was associated with a 
twofold increase of neutral peptide generation throughout the entire substrate 
peak,  indicating that  heating either increased substrate  susceptibility or de- 
stroyed an inactivator of the neutral peptide since a-l-antitrypsin was absent 
from the starting material. Sephadex  G-150  gel  filtration of the pooled, con- 
centrated substrate-containing fractions (Fig. 7) revealed an ascending region 
in which neutral peptide generation was not augmented by the heat-inactiva- 
tion effect and a descending region in which heating increased neutral peptide 
generation. The  presence  of a  heat-labile neutral  peptide  inactivator in  the 
descending region was established by incubating 100 ng BK Eq of Sephadex 
G-15  purified neutral  peptide  with  200  ul  of unheated  substrate-containing 
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FIO. 7.  Sephadex G-150 filtration of plasma substrate for neutrophil protease obtained by 
QAE Sephadex chromatography of plasma from the  (null)  a-l-antitrypsin-deficient  patient. 
Values for protein concentration  are net absorption at 600 nM. The column was previously 
calibrated with aldolase, human serum albumin, and chymotrypsinogen which peaked in frac- 
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fraction for 30 rain at 37°C.  Complete inactivation of neutral peptide occurred 
in those fractions of substrate whose capacity to generate neutral peptide was 
augmented by heating, while there was no inactivation in the substrate frac- 
tions unaffected by heating. 
DISCUSSION 
A biologically active, low molecular weight neutral peptide mediator cleaved 
from a plasma protein substrate by a serine protease associated with the neu- 
trophil  membrane has been  recognized. The  formation of neutral  peptide is 
exquisitely controlled by the action of a-l-antitrypsin on the neutrophil pro- 
tease, and  the peptide mediator is inactivated by a  plasma  factor separable 
from the other reactants. The neutrophil protease responsible for neutral pep- 
tide  generation  is  distinguished  from  a-l-antitrypsin  inhibitable  lysosomal 
esterases such as neutral leukocyte protease (19),  elastase (20),  and the kinin- 
forming enzyme (3) by its subcellular location (Fig. 5)  and from plasma kalli- 
krein by the failure of a-2-macroglobulin to inhibit its action (4). The substrate 
is distinguished antigenically  2 and chromatographically from kininogen (Fig. 
6), and there are critical physical, chemical, and functional differences between 
neutral  peptide  and bradykinin. This  does not preclude  the possibility that 
any of the five recognized components may participate in other reaction path- 
ways of host defense and inflammation. 
The biologically active mediator generated by the interaction of the neutro- 
phil protease and the plasma substrate was designated neutral peptide because 
of its isoelectric point of 7.3-7.5  and inactivation by chymotrypsin and tryp- 
sin. Only a  single functional species of neutral peptide was recognized by iso- 
electric focusing, descending paper chromatography, and Sephadex G-15 filtra- 
tion. Sephadex G-15 filtration revealed a tool wt for neutral peptide indistin- 
guishable from the marker nonapeptide bradykinin, approximately 1,000 (Fig. 
2).  Neutral peptide elicits a slow contraction of the isolated guinea pig ileum 
pretreated with atropine and mepyramine, has little activity on the estrous rat 
uterus and increases vascular permeability in guinea pig skin. 
The  neutrophil  enzyme  responsible  for  the  generation of  neutral  peptide 
(Fig. 1) was not detectable in purified mononuclear cells, was labile to heating 
at 61°C for 15 min, and was a tryptic serine protease based on its inactivation 
by DFP (21) and inhibition by lima bean and soybean trypsin inhibitors (Fig. 
3). Several lines of evidence suggest that the protease is available on the mem- 
brane possibly as an ectoenzyme. The protease  activity was present only in 
the excluded vol of gel filtration of the crude neutrophil extract through Sepha- 
rose 4B  in association with  the membrane marker 5'-nucleotidase, implying 
association w!th particles of a tool wt greater than 10 million. Subcellular frac- 
tionation of purified human neutrophils located the neutral peptide-generating 
activity in the heaviest fraction containing predominantly fragments  of cells 
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with cytoplasmic membrane  (Fig. 5)  and failed to disclose  activity with the 
fractions  containing  principally  nuclei,  lysosomes,  or  cytoplasm.  Finally, 
¢z-l-antitrypsin  treatment  of  intact  neutrophils  with  an  amount  known  to 
inhibit crude neutrophil extract by about 50%  (Fig. 4)  inhibited both intact 
cells and their broken cell product by that same percent. As o~-l-antitrypsin is 
a  plasma protein,  it would not be expected to  enter cells  rapidly by simple 
diffusion and it thus seems likely that its inhibition of the neutrophil serine 
protease of intact cells occurs at the membrane. 
The use of heat inactivation at 61°C for 2 h proved critical to the formation 
and stability of the neutral peptide in normal plasma and hence to the isola- 
tion of substrate from plasma. The heat-labile inhibitor of neutral peptide for- 
mation  in  plasma  proved  to  be  o~-l-antitrypsin,  a-l-antitrypsin  chromato- 
graphed  with  substrate  on  anion  exchange  chromatography and  thus  only 
substrate isolated from a (null) a-l-antitrypsin deficient patient yielded neutral 
peptide without a heat inactivation step before interaction with the neutrophil 
protease (Fig. 7). An inactivator chromatographed with the substrate on QAE 
Sephadex but was distinguished on Sephadex G-150 filtration by its appearance 
only on the descending limb of the substrate peak (Fig. 7). 
The exquisite sensitivity of the neutrophil  serine protease  to purified o~-l- 
antitrypsin (Fig. 4) was recognized by the capacity of 1% of the normal plasma 
concentration of  a-l-antitrypsin  to  suppress  the  neutral  peptide-generating 
activity derived from the neutrophils contained in the same vol of whole blood. 
Indeed, neutral peptide generation in plasma occurred only with plasma of a 
unique patient with no detectable o~-l-antitrypsin. The recognition of a neutro- 
phil  protease  with  a-l-antitrypsin  as  the  only readily demonstrable  control 
protein  raises  the possibility that neutrophil accumulation might overwhelm 
the  limited  levels  in  cz-l-antitrypsin-deficient  persons,  thereby  permitting 
cleavage of substrate for neutral peptide as well as other undefined protease 
activity. 
SUMMARY 
A  biologically active  neutral  peptide  mediator  is  cleaved  from  a  plasma 
protein substrate by an a-l-antitrypsin-inhibitable serine protease apparently 
residing on the membrane of the human neutrophil. The peptide mediator has 
an approximate mol wt of 1,000, and is distinguished from the kinin peptides 
by  a  neutral  isoelectric  point,  susceptibility to  inactivation  by  trypsin  as 
well  as  chymotrypsin and  activity  on  the  isolated,  atropinized,  and  anti- 
histamine-treated guinea pig ileum with relatively little action on the estrous 
rat uterus. The neutrophil protease is fully inhibitable by DFP, trypsin inhibi- 
tots from lima or soy bean, and a-l-antitrypsin and is associated with the high 
tool wt fragments of the neutrophil and not the nuclear, lysosomal, or cyto- 
plasmic subcellular fraction. The substrate has an approximate tool wt of 90,000 
and is chromatographically separable from kininogen. The exquisite sensitivity BRUCE U.  WINTROUB, EDWARD  J.  GOETZL,  K.  :FRANK AUSTEN  823 
of the neutrophil protease to a-l-antitrypsin was established both by inhibition 
with  highly  purified  ~-l-antitrypsin  and  by  the  inability  of  the  protease  to 
generate  detectable  neutral  peptide  in  a  homozygous  (ZZ)  a-l-antitrypsin- 
deficient  patient  without  heat  inactivation  of the  residual  inhibitor.  On  the 
other  hand,  plasma  from a  (null)  a-l-antitrypsin-deficient  patient  supported 
neutral peptide generation and revealed an additional factor which inactivated 
neutral peptide. 
We are grateful  for the excellent technical assistance of Ms. Carol  Sena and  Ms. Janet 
Woods. 
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